id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-323095-q8tj826i	Sokolowska, Milena	Outsmarting SARS-CoV-2 by empowering a decoy ACE2	2020-11-03		.txt	text/plain	1473	85	50	Along with the current efforts to develop high-affinity neutralizing antibodies, Chan and colleagues engineered the soluble variant of human ACE2 with enhanced binding to the spike protein, outranking the soluble wild-type protein in blocking SARS-CoV-2 infection in vitro. There are currently a few therapeutic approaches focused on blocking SARS-CoV-2 binding to its key receptor, an angiotensin-converting enzyme 2 (ACE2), or on inhibition of virus spike cleavage (Fig. 1a) . 2 Therefore, other approaches are also intensively studied including soluble recombinant human ACE2 (rhACE2) or peptide-based binders, developed to block SARS-CoV-2-RBD-ACE2 binding interface or small molecule inhibitors blocking the host cell proteases, such as TMPRSS2 or furin, block virus fusion with the host cell. Therefore, in designing the soluble ACE2 (sACE2) variant the authors introduced the combinations of 3-7 mutations, which gave the large increases in S binding. Engineered soluble construct of ACE2 with enhanced affinity to SARS-CoV-2 spike RBD opens up several possibilities of its usage in the current pandemics.	./cache/cord-323095-q8tj826i.txt	./txt/cord-323095-q8tj826i.txt